BioInvent announces new BI-505 preclinical data on multiple myeloma

May 22, 2017

The most common clinical adverse events were grade 1 or 2 and included flu-like symptoms, pyrexia, headache, and fatigue. These were most frequently seen at the onset of treatment. The clinically most relevant adverse events were fully reversible central nervous system (CNS) events. A key objective of this study was to optimize the type and timing of steroid administration to mitigate the risk of developing CNS adverse events. Notably, no discontinuations due to CNS events were observed in the five patients who received an optimized steroid schedule including dexamethasone administration starting 12 hours before the start of blinatumomab infusion.

"With an improved steroid pre-medication schedule, we have successfully treated patients with relapsed diffuse large B cell lymphoma at the blinatumomab target dose," said Jan Fagerberg, M.D., Ph.D., Micromet's Senior Vice President and Chief Medical Officer. "We plan to initiate in 2012 a phase 2 trial in patients with diffuse large B cell lymphoma."

Source: Micromet